Microglia, amyloid, and glucose metabolism in Parkinson's disease with and without dementia. - Test2 - elhamkhani - TriplyDB

Microglia, amyloid, and glucose metabolism in Parkinson's disease with and without dementia.

Microglia, amyloid, and glucose metabolism in Parkinson's disease with and without dementia.

http://www.wikidata.org/entity/Q36775208

about

Beneficial effects of nicotine, cotinine and its metabolites as potential agents for Parkinson's disease TSPO imaging in parkinsonian disorders Insights into Neuroinflammation in Parkinson's Disease: From Biomarkers to Anti-Inflammatory Based Therapies M1 and M2 immune activation in Parkinson's Disease: Foe and ally?Neuroimaging of Parkinson's disease: Expanding views.Recent imaging advances in neurology.Biomarkers for dementia and mild cognitive impairment in Parkinson's disease.Translocator Protein-18 kDa (TSPO) Positron Emission Tomography (PET) Imaging and Its Clinical Impact in Neurodegenerative Diseases Radiation dosimetry and biodistribution of the translocator protein radiotracer [(11)C]DAA1106 determined with PET/CT in healthy human volunteers.Imaging biomarkers in Parkinson's disease and Parkinsonian syndromes: current and emerging concepts.Image-derived input function derived from a supervised clustering algorithm: methodology and validation in a clinical protocol using [11C](R)-rolipram Benzoyl chloride derivatization with liquid chromatography-mass spectrometry for targeted metabolomics of neurochemicals in biological samples Alternative mitochondrial electron transfer for the treatment of neurodegenerative diseases and cancers: Methylene blue connects the dots.PET imaging of inflammation biomarkers.Neuroimaging of Inflammation in Memory and Related Other Disorders (NIMROD) study protocol: a deep phenotyping cohort study of the role of brain inflammation in dementia, depression and other neurological illnesses.Imaging of neuroinflammation in parkinsonian syndromes with positron emission tomography.What can biomarkers tell us about cognition in Parkinson's disease?Imaging the role of amyloid in PD dementia and dementia with Lewy bodies.Cholinesterase inhibitors for Parkinson's disease: a systematic review and meta-analysis.Imaging β-amyloid using [(18)F]flutemetamol positron emission tomography: from dosimetry to clinical diagnosis.Glucose consumption of inflammatory cells masks metabolic deficits in the brain.Molecular Imaging and Updated Diagnostic Criteria in Lewy Body Dementias.Tau/α-synuclein ratio and inflammatory proteins in Parkinson's disease: An exploratory study.Microglial activation in Parkinson's disease using [18F]-FEPPA.In vivo PET imaging of neuroinflammation in Alzheimer's disease.Microglial phenotypes in Parkinson's disease and animal models of the disease.l-DOPA-induced dyskinesia in Parkinson's disease: Are neuroinflammation and astrocytes key elements?Neuroinflammation in Neurodegenerative Disorders-a Review.Parkinson's disease: Microglial/macrophage-induced immunoexcitotoxicity as a central mechanism of neurodegeneration Targeting Microglial Activation States as a Therapeutic Avenue in Parkinson's Disease.Serum immune markers and disease progression in an incident Parkinson's disease cohort (ICICLE-PD).Amyloid PET imaging: applications beyond Alzheimer's disease.Assessment of change in glucose metabolism in white matter of amyloid-positive patients with Alzheimer disease using F-18 FDG PET.Potential clinical utility of multiple system atrophy biomarkers.Inflammation alters AMPA-stimulated calcium responses in dorsal striatal D2 but not D1 spiny projection neurons.Regulation and effects of neurotrophic factors after neural stem cell transplantation in a transgenic mouse model of Alzheimer disease.Acetyl-L-Carnitine via Upegulating Dopamine D1 Receptor and Attenuating Microglial Activation Prevents Neuronal Loss and Improves Memory Functions in Parkinsonian Rats.An early and late peak in microglial activation in Alzheimer's disease trajectory.Extrastriatal spreading of microglial activation in Parkinson's disease: a positron emission tomography study.Does Microglial Activation Influence Hippocampal Volume and Neuronal Function in Alzheimer's Disease and Parkinson's Disease Dementia?

P2860

Q21131066-199BB9A8-1572-4171-AD2E-4CD598FAD005 Q26747214-B0BF78B9-348A-4FF3-B4A8-2BB1F9D21BCA Q26795984-F672A421-A191-4427-AA69-8483259866FF Q27024667-CC87B29F-BF3F-43BC-A639-B679C3003F74 Q28387732-233B0999-D76E-4812-8372-8DCC67C4B6D6 Q30916063-8E23E122-ED66-45EC-88CD-53D0EC98BDDB Q31097119-577E0ECD-2194-4A20-9B89-22BFC6467694 Q33624586-33DBA410-FCA9-4113-B1B6-1A23D9DDEFE6 Q34315675-528B3403-C7D0-4735-A3FB-04C591597823 Q34554452-6CED04EC-DB2D-438F-8E4A-80B01FD8780A Q35106668-3C897DA1-DA26-42B2-96BA-6950D25F222D Q36835701-18DA0EFE-82FE-4A0C-B6B7-3C8E1CCBF5FB Q36913723-1D50E09E-7F6C-4BA3-9C48-9AA608913DB2 Q36997603-DFDBAD7F-151A-4127-8FA4-754B06B9B787 Q37576743-A0936C74-3497-4316-9856-3EE192668224 Q38154242-727716A9-6AFD-4880-9BBF-88F9B2D5FFBF Q38206497-49FE7756-FAED-4239-A7C3-2EE01E588060 Q38228098-ECC6CF66-986A-4266-A456-9B5B25A5859A Q38249953-82D2191F-2BCB-4E93-909C-E7C6734D215E Q38600277-E29E206D-5AC8-44B2-9CDB-8AF8F65B5944 Q38629592-2B43822E-D4A2-4D44-9BCE-82AE0F3C6B69 Q38642389-C1138159-ECFE-4511-9BD8-D8A14A597D93 Q38761739-BF43FDBA-95A9-400C-B977-3CF5D88BCD2D Q38770651-49264C7A-5961-4337-8936-AC0A07808FC0 Q38779574-08881F99-5223-4E2F-B3CD-14AEEF44D126 Q38815779-173F36AD-55A6-456E-AE61-93A21517DCB3 Q38951947-C04994AB-7BFF-4272-9E55-904E5C6ACA63 Q39173756-68150A3C-05B3-420A-BA62-8F2BD02011E6 Q39327711-7B7C274A-FFFC-4411-8648-12E0FECA2E04 Q39392775-7660AE7F-9702-42EA-8255-8AA9E30ECADC Q39901740-1855A81F-E987-46EC-A489-DDDDC71841EF Q43161462-13CDD3F4-16B9-4D3A-A56D-F1BB5BC359D1 Q47223955-E63A54C0-FF53-4413-A572-084DD82B2C2D Q47663712-04C63461-BDA7-46A1-9EC1-C6CB267DE0CD Q47786283-1EB089CD-0860-400C-AA87-E2A3AB5EFB80 Q47980519-BA6C379A-BEB8-4422-8A3E-652492808F87 Q48152985-8AAAC683-7C7C-4019-8C09-C07E2818FC17 Q48339994-CDD391CA-E721-4A40-AC96-73F7E9755FEF Q48678943-9C5F179D-3185-4C8B-9876-62FF84027C0D Q52141280-B70F4DC7-0EA1-4FBE-AAEC-D851D10A45A7

P2860

Microglia, amyloid, and glucose metabolism in Parkinson's disease with and without dementia.

http://www.wikidata.org/entity/Q36775208

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Microglia, amyloid, and glucos ...... ase with and without dementia.

@ast

Microglia, amyloid, and glucos ...... ase with and without dementia.

@en

type

label

Microglia, amyloid, and glucos ...... ase with and without dementia.

@ast

Microglia, amyloid, and glucos ...... ase with and without dementia.

@en

prefLabel

Microglia, amyloid, and glucos ...... ase with and without dementia.

@ast

Microglia, amyloid, and glucos ...... ase with and without dementia.

@en

P1433

Q36775208-8CA4E7EA-EB1A-43A6-9027-E1652B4B0EE7

P1476

Q36775208-B8899583-E819-4977-BA7D-E0665753EE6A

P2093

Q36775208-14357377-1FB2-4400-92A4-2ADE567EC040

Q36775208-A436678B-1D8A-4DFE-95B0-A5612ACBE921

Q36775208-A765A4D6-CF0D-4C1E-9F49-CA51380EA2FB

Q36775208-A98C9F8D-DBFC-41C9-8C56-1310957D9173

Q36775208-E5B19A11-4E09-4CA3-9B64-4637CE1B1010

P2860

Q36775208-003C4407-0F8E-45DF-991F-1FE8E859B7BF

Q36775208-021EC229-DF6D-4055-A213-C40E791D6E83

Q36775208-044D6282-5E12-43F4-994B-21BB468DC9A4

Q36775208-09E91B35-F3CA-41A6-9FD1-3091D2433CDF

Q36775208-0E5F031B-3545-4989-8946-8522DC2A0167

Q36775208-0F9B3641-654F-43C4-9E68-CE47F5AC8568

Q36775208-14582344-9D78-487C-A65E-4B672F33E5C5

Q36775208-17A14DC3-639F-4E92-B780-7646E87F8537

Q36775208-1A19426B-D064-4006-87FE-C27A04A5FA3D

Q36775208-24D3D5E7-AE22-4292-B699-78B6B32D7E5B

P2888

Q36775208-60E64904-18F1-49E1-A70C-1D06FADDAFA8

P304

Q36775208-B4A7C3FE-31E6-4477-8A47-8C5ADB08574C

P31

Q36775208-8A6F26A5-4345-4B42-8A91-7230A70743B8

P356

Q36775208-83F50EB6-D7F2-4916-BF5F-76E2FCF71E51

P407

Q36775208-33F90D8D-8C91-4B3E-9D4F-563ABC4DBEB9

P433

Q36775208-52DC14C8-4FCD-4884-BDA4-BA1F27094252

P478

Q36775208-C00775AA-73A3-4BBE-95E7-D8BF4794B6E5

P50

Q36775208-6B477881-26D6-4809-B9B2-771DFA18A49D

Q36775208-844692BE-FE65-4D2F-AC2A-477299DBAA99

Q36775208-8ABFFB74-648A-49F9-B8BD-148AE0003EB2

Q36775208-A08A88FD-C36E-420A-9965-19EA670A65A3

P577

Q36775208-E1035DE0-3498-4DE0-9981-D84E2BEEA22A

P698

Q36775208-42EB1A68-D4B5-46C7-8C0C-4C88E693E39B

P921

Q36775208-492231FD-3981-4C17-9CA9-808A309EF7BA

Q36775208-64DAF4E3-8387-4561-BAF9-E5B7A024C61F

Q36775208-8474BF14-69C9-49AE-9BE5-9C5881894739

P932

Q36775208-6070B708-8EFD-4C49-8DDA-565F44262C8C

P356

P1433

Neuropsychopharmacology

P1476

Microglia, amyloid, and glucos ...... ase with and without dementia.

@en

P2093

Giorgio Gelosa

http://www.w3.org/2001/XMLSchema#string

Imtiaz Ahmed

http://www.w3.org/2001/XMLSchema#string

Paul Edison

http://www.w3.org/2001/XMLSchema#string

Rainer Hinz

http://www.w3.org/2001/XMLSchema#string

Zhen Fan

http://www.w3.org/2001/XMLSchema#string

P2860

Cortical hypometabolism and hypoperfusion in Parkinson's disease is extensive: probably even at early disease stages.

The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.

Intellectual impairment in Parkinson's disease: clinical, pathologic, and biochemical correlates.

Inflammation in neurodegenerative disease--a double-edged sword.

The role of glial reaction and inflammation in Parkinson's disease.

Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia.

Inflammation and the degenerative diseases of aging.

Clinical diagnostic criteria for dementia associated with Parkinson's disease.

Imaging amyloid deposition in Lewy body diseases

The use of PET in Alzheimer disease.

P2888

P304

938-949

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NPP.2012.255

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

38

http://www.w3.org/2001/XMLSchema#string

P50

David J. Brooks

Federico Turkheimer

Kallol Ray Chaudhuri

P577

2012-12-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23303049

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

3629382

http://www.w3.org/2001/XMLSchema#string